Novartis closes technical R&D site in San Diego as part of ongoing restructure

An R&D center in San Diego is the latest area to be impacted by Novartis’ ongoing global development restructure, the company has confirmed.

The Swiss Big Pharma will conduct a “phased exit” from the Technical Research and Development (TRD) site at Campus Point Drive, with “final closure anticipated by end of 2025,” the company confirmed in an email to Fierce Biotech.